{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 36 of 128', '5.3 Trial rationale', 'The purpose of this phase 2b trial is to establish a dose-response signal and to evaluate the', 'efficacy and safety of delgocitinib (1, 3, 8, and 20 mg/g), formulated as a cream for topical', 'use, in the treatment of subjects with mild to severe chronic hand eczema. The results from', 'this trial will support further development in phase 3 with regards to e.g., dose selection and', 'treatment duration.', 'There is a clear unmet need for new treatment options in the treatment of patients suffering', 'from chronic hand eczema. Based on currently available non-clinical and clinical data,', 'delgocitinib has the potential to become a novel local-acting anti-inflammatory and', 'immunosuppressive agent with skin barrier improving properties (10) for topical use in', 'chronic hand eczema. There is a reasonable expectation that delgocitinib in a cream', 'formulation will prove to be an effective and well-tolerated treatment based on the mechanism', 'of action, and thereby facilitate the everyday lives of affected patients.', '5.4 Justification for dose', 'CCI']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 37 of 128', 'CCI', '5.5 Ethical considerations', 'This trial will be conducted in accordance with the ethical principles that have their origins in', 'the Declaration of Helsinki, the International Council for Harmonisation (ICH) Good Clinical', 'Practice (GCP) guidelines, in compliance with the approved protocol, and applicable', 'regulatory requirements.', 'Risks associated with treatment in this clinical trial (risks of experiencing significant adverse', 'reactions associated with dermal or systemic exposure to delgocitinib) are considered', 'minimal.', 'The trial design chosen for this efficacy and safety trial with delgocitinib cream is regarded as', 'ethically justified and adherent with ethical requirements. The efficacy and safety of', 'delgocitinib cream will be evaluated in adults suffering from mild to severe chronic hand', 'eczema who may benefit from treatment in the trial. Pregnant or breastfeeding women and', 'women trying to become pregnant will not be enrolled in the trial. Women of childbearing', 'potential must agree to use a highly effective method of contraception to prevent pregnancy', 'during the trial.', 'Trial subjects will be informed at the screening visit that trial procedures prior to baseline', '(Day 1) may warrant an alteration of their ongoing concomitant treatments. As applicable for', 'the entire trial, the subjects will be instructed to contact the investigator if their chronic hand', 'eczema worsens significantly.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 38 of 128', 'In accordance with the current version of the ICH-GCP guidelines, qualified medical', 'personnel employed by LEO will be readily available to advise on trial-related medical', 'questions. Medical monitoring will be performed throughout the trial. Safety data will be', 'reviewed regularly by Global Pharmacovigilance at LEO to ensure routine signal detection.', '5.6 Benefit/risk assessment', 'There is an unmet medical need for new therapies for use in patients with mild to severe', 'chronic hand eczema. Chronic hand eczema is a physically and psychologically challenging', 'disease often accompanied by distress due to its visible location. Current treatment options are', 'limited to only one approved therapeutic product (only in EU) with significant safety', 'precautions, which is only appropriate for patients with severe chronic hand eczema. Other', 'treatment options include topical steroids and calcineurin inhibitors, which lack a valid', 'benefit/risk evaluation by competent regulatory authorities (as further described in', 'Section 5.1).', 'No important identified risks have been documented during the overall non-clinical and', 'clinical development of delgocitinib to date. A detailed overview of non-clinical and clinical', \"data on delgocitinib is available in the current Investigator's Brochure.\", 'To ensure the safety and wellbeing of subjects participating in this clinical trial, safety', 'monitoring will be evaluated as described in Section 11.4. The risks associated with the', 'following invasive trial procedures are considered minimal. Blood samples can be considered', 'a low risk procedure. Skin biopsies are optional to the subject. The size of the skin biopsies', \"should not necessitate suturing, but suturing can be performed at the investigator's discretion.\", 'The risk associated with a skin biopsy, including secondary infection, is considered low. Skin', 'barrier function is measured using non-invasive or minimally invasive techniques, and the', 'risk associated with these techniques is considered low.', 'Altogether, the risks associated with participating in this clinical trial are considered very low', 'and outweighed by the benefit of a potential future treatment option for chronic hand eczema.', 'There is an opportunity for a positive treatment effect for the subjects participating in this', 'clinical trial based on the currently available clinical data.']\n\n###\n\n", "completion": "END"}